134 related articles for article (PubMed ID: 31917753)
1. Brief Report: Interferon-γ-Inducible Protein 10-A Potential Marker for Targeted Viral Load Monitoring of Antiretroviral Treatment?
Reepalu A; Arimide DA; Balcha TT; Björkman P; Medstrand P
J Acquir Immune Defic Syndr; 2020 Apr; 83(5):475-478. PubMed ID: 31917753
[TBL] [Abstract][Full Text] [Related]
2. Interferon-γ-Inducible Protein 10 (IP-10) Kinetics after Antiretroviral Treatment Initiation in Ethiopian Adults with HIV.
Thorman J; Björkman P; Marrone G; Tolera Balcha T; Tesfaye F; Abdissa T; Naniche D; Medstrand P; Reepalu A
Microbiol Spectr; 2021 Dec; 9(3):e0181021. PubMed ID: 34908450
[TBL] [Abstract][Full Text] [Related]
3. Interferon-γ-Inducible Protein 10 (IP-10) as a Screening Tool to Optimize Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings.
Pastor L; Casellas A; Rupérez M; Carrillo J; Maculuve S; Jairoce C; Paredes R; Blanco J; Naniche D
Clin Infect Dis; 2017 Oct; 65(10):1670-1675. PubMed ID: 29020145
[TBL] [Abstract][Full Text] [Related]
4. Performance of Galectin-9 for Identification of HIV Viremia in Adults Receiving Antiretroviral Therapy in a Resource-Limited Setting.
Thorman J; Björkman P; Sasinovich S; Tesfaye F; Mulleta D; Medstrand P; Reepalu A
J Acquir Immune Defic Syndr; 2023 Jul; 93(3):244-250. PubMed ID: 36961948
[TBL] [Abstract][Full Text] [Related]
5. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
[TBL] [Abstract][Full Text] [Related]
6. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.
Dravid AN; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Wadia RS
Medicine (Baltimore); 2018 Feb; 97(8):e9969. PubMed ID: 29465595
[TBL] [Abstract][Full Text] [Related]
7. Non-uptake of viral load testing among people receiving HIV treatment in Gomba district, rural Uganda.
Nakalega R; Mukiza N; Kiwanuka G; Makanga-Kakumba R; Menge R; Kataike H; Maena J; Akello C; Atuhaire P; Matovu-Kiweewa F; Ndikuno-Kuteesa C; Debem H; Mujugira A
BMC Infect Dis; 2020 Oct; 20(1):727. PubMed ID: 33023498
[TBL] [Abstract][Full Text] [Related]
8. Socio-economic condition and lack of virological suppression among adults and adolescents receiving antiretroviral therapy in Ethiopia.
Plymoth M; Sanders EJ; Van Der Elst EM; Medstrand P; Tesfaye F; Winqvist N; Balcha T; Björkman P
PLoS One; 2020; 15(12):e0244066. PubMed ID: 33320900
[TBL] [Abstract][Full Text] [Related]
9. CSF Inflammation Markers Associated with Asymptomatic Viral Escape in Cerebrospinal Fluid of HIV-Positive Individuals on Antiretroviral Therapy.
Guha D; Misra V; Yin J; Gabuzda D
Viruses; 2023 Aug; 15(9):. PubMed ID: 37766236
[TBL] [Abstract][Full Text] [Related]
10. Field performance and cost-effectiveness of a point-of-care triage test for HIV virological failure in Southern Africa.
Saura-Lázaro A; Bock P; Bogaart EVD; van Vliet J; Granés L; Nel K; Naidoo V; Scheepers M; Saunders Y; Leal N; Ramponi F; Paulussen R; de Wit TR; Naniche D; López-Varela E
J Int AIDS Soc; 2023 Oct; 26(10):e26176. PubMed ID: 37803882
[TBL] [Abstract][Full Text] [Related]
11. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
Kadima J; Patterson E; Mburu M; Blat C; Nyanduko M; Bukusi EA; Cohen C; Oyaro P; Abuogi L
PLoS One; 2018; 13(11):e0200242. PubMed ID: 30412576
[TBL] [Abstract][Full Text] [Related]
12. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
Ladak F; Socias E; Nolan S; Dong H; Kerr T; Wood E; Montaner J; Milloy MJ
Antivir Ther; 2019; 24(1):19-25. PubMed ID: 30230474
[TBL] [Abstract][Full Text] [Related]
13. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
[TBL] [Abstract][Full Text] [Related]
14. HIV RNA Suppression during and after Pregnancy among Women in the HIV Outpatient Study, 1996 to 2015.
Patel M; Tedaldi E; Armon C; Nesheim S; Lampe M; Palella F; Novak R; Sutton M; Buchacz K;
J Int Assoc Provid AIDS Care; 2018; 17():2325957417752259. PubMed ID: 29357772
[TBL] [Abstract][Full Text] [Related]
15. Possible role of plasma Galectin-9 levels as a surrogate marker of viremia in HIV infected patients on antiretroviral therapy in resource-limited settings.
Shete A; Dhayarkar S; Dhamanage A; Kulkarni S; Ghate M; Sangle S; Medhe U; Verma V; Rajan S; Hattori T; Gangakhedkar R
AIDS Res Ther; 2020 Jul; 17(1):43. PubMed ID: 32678033
[TBL] [Abstract][Full Text] [Related]
16. Routine versus Targeted Viral Load Strategy among Patients Starting Antiretroviral in Hanoi, Vietnam.
Pollack TM; Duong HT; Pham TT; Nguyen TD; Libman H; Ngo L; McMahon JH; Elliott JH; Do CD; Colby DJ
J Int AIDS Soc; 2019 Mar; 22(3):e25258. PubMed ID: 30897303
[TBL] [Abstract][Full Text] [Related]
17. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
[TBL] [Abstract][Full Text] [Related]
18. Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access.
Jain V; Byonanebye DM; Liegler T; Kwarisiima D; Chamie G; Kabami J; Petersen ML; Balzer LB; Clark TD; Black D; Thirumurthy H; Geng EH; Charlebois ED; Amanyire G; Kamya MR; Havlir DV;
J Acquir Immune Defic Syndr; 2014 Mar; 65(3):327-32. PubMed ID: 24146022
[TBL] [Abstract][Full Text] [Related]
19. HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.
Myer L; Phillips TK; McIntyre JA; Hsiao NY; Petro G; Zerbe A; Ramjith J; Bekker LG; Abrams EJ
HIV Med; 2017 Feb; 18(2):80-88. PubMed ID: 27353189
[TBL] [Abstract][Full Text] [Related]
20. SESOTHO trial ("Switch Either near Suppression Or THOusand") - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa.
Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Achieng B; Sepeka M; Tlali K; Sao L; Thin K; Klimkait T; Battegay M; Labhardt ND
BMC Infect Dis; 2018 Feb; 18(1):76. PubMed ID: 29433430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
